Potent inhibitory activity of chimeric oligonucleotides targeting two different sites of human telomerase

Oligonucleotides

Volumn 15, Issue 4, 2005, Pages 255-268

  Matthes, Eckart ^a   Lehmann, Christine ^a   Stulich, Marianne ^a   Wu, Yong ^a,b   Dimitrova, Lora ^a   Uhlmann, Eugen ^c,d   Von Janta Lipinski, Martin ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYLRIBONUCLEOSIDE; 2' O METHYLRIBOSYL PHOSPHODIESTER; LIPOFECTIN; OLIGOMER; OLIGONUCLEOTIDE; PHOSPHODIESTER; PHOSPHORAMIDIC ACID DERIVATIVE; PHOSPHOROTHIOIC ACID DERIVATIVE; RIBONUCLEOSIDE DERIVATIVE; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER THERAPY; CELL LYSATE; CHIMERA; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN MOTIF; RIBONUCLEIC ACID TEMPLATE; RNA SEQUENCE; STRUCTURE ACTIVITY RELATION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR CELL;

BASE SEQUENCE; CELL LINE; ENZYME INHIBITORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; POLYMERS; TELOMERASE;

EID: 30844444600     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2005.15.255     Document Type: Article

References (39)

1. AUTEXIER, C. (1999). Telomerase as a possible target for anticancer therapy. Chem. Biol. 6, R299-R303.
2. CHENG, Y.-C., GAO, W.-Y., and HAN, F.-S. (1991). Phosphorothioate oligonucleotides as potential antiviral compounds against human immunodeficiency virus and herpes viruses. Nucleosides Nucleotides 10, 155-166.
3. COUNTER, C.M., MEYERSON, M., EATON, E.N., and WEINBERG, R.A. (1997). The catalytic subunit of yeast telomerase. Proc. Natl. Acad. Sci. USA 94, 9202-9207.
4. ELAYADI, A.N., BRAASCH, D.A., and COREY, D.R. (2002). Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41, 9973-9981.
5. ELAYADI, A.N., DEMIEVILLE, A., WANCEWICZ, E.V., MONIA, B.P., and COREY, D.R. (2001). Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: Effects of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. 29, 1683-1689.
6. FENG, J., FUNK, W.D., WANG, S.-S., WEINREICH, S.L., AVILION, A.A., CHIU, C.-P., ADAMS, R.R., CHANG, E., ALLSOPP, R.C., YU, J., LE, S., WEST, M.D., HARLEY, C.B., ANDREWS, W.H., GREIDER, C.W., and VILLEPONTEAU, B. (1995). The RNA component of human telomerase. Science 269, 1236-1241.
7. GLUKHOV, A.I., ZIMNIK., O.V., GORDEEV, S.A., and SEVERIN, S.E. (1998). Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem. Biophys. Res. Commun. 248, 368-371.
8. GRYAZNOV, S.M. (1999). Oligonucleotide N3′ → P5′ phosphoramidates as potential therapeutic agents. Biochim. Biophys. Acta 1489, 131-140.
9. GRYAZNOV, S.M., and LETZINGER, R.L. (1999). Synthesis and properties of oligonucleotides containing aminodeoxythymidine units. Nucleic Acids Res. 22, 3403-3409.
10. HAHN, W.C., STEWART, S.A., BROOKS, M.W., YORK, S.G., EATON, E., KURACHI, A., BEIJERSBERGEN, R.L., KNOLL, J.H.M., MEYERSON, M., and WEINBERG, R.A. (1999). Inhibition of telomerase limits the growth of human cancer cells. Nature Med. 5, 1164-1170.
11. HAMILTON, S.E., SIMMONS, C.G., KATHIRIYA, I.S., and COREY, D.R. (1999). Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6, 343-351.
12. HAMMOND, P.W., LIVELY, T.N., and Cech, T.R. (1997). The anchor site of telomerase from Euplotes adiculatus revealed by photo-cross-linking to single- and double-stranded DNA primers. Mol. Cell. Biol. 17, 296-308.
13. HARRISON, J.G., FRIER, C., LAURANT, R., DENNIS, R., RANEY, K.D., and BALASUBRAMANIAN, S. (1999). Inhibition of human telomerase by PNA-cationic peptide conjugates. Bioorg. Med. Chem. Lett. 9, 1273-1278.
14. HERBERT, B.-S., PITTS, A.E., BAKER, S.I., HAMILTON, S.E., WRIGHT, W.E., SHAY, J.W., and COREY, D.R. (1999). Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA 96, 14276-14281.
15. HERBERT, B.-S., PONGRACZ, K., SHAY, J.W., and GRYAZNOV, S.M. (2002). Oligonucleotide N3′ → P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 21, 638-642.
16. KANAZAWA, Y., OHKAWA, K., UEDA, K., MITA, E., TAKEHARA, T., SASAKI, Y., KASAHARA, A., and HAYASHI, N. (1996). Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225, 570-576.
17. KIM, N.W., PIATYSZEK, M.A., PROWSE, K.R., HARLEY, C.B., WEST, M.D., HO, P.L.C., COVIELLO, G.M., WRIGHT, W.E., WEINRICH, S.L., and SHAY, J.W. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015.
18. KONDO, S., KONDO, Y., LI, G., SILVERMAN, R.H., and COWELL, J.K. (1998). Targeted therapy of human malignant glioma in a mouse model by 2-5 A antisense directed against telomerase RNA. Oncogene 16, 3323-3330.
19. KONDO, Y., KOMATA, T., and KONDO, S. (2001). Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int. J. Oncol. 18, 1287-1292.
20. LINGNER, J., HUGHES, T.R., SHEVCHENKO, A., MANN, M., LUNDBLAD, V., and CECH, T.R. (1997). Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276, 561-567.
21. MAJUMDAR, C., STEIN, C.A., COHEN, J.S., BRODER, S., and WILDO, S.H. (1989). Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligonucleotide. Biochemistry 28, 1340-1346.
22. MATA, J.E., JOSHI, S.S., PALEN, B., PIRRUCCELLO, S.J., JACKSON, J.D., ELIAS, N., PAGE, T.J., MEDLIN, K.L., and IVERSEN, P.L. (1997). A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol. Appl. Pharmacol. 144, 189-197.
23. MATTHES, E., and LEHMANN, C. (1999). Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res. 27, 1152-1158.
24. MOELLING, K., SCHULZE, T., and DIRINGER, H. (1989). Inhibition of human immunodeficiency virus type1 by sulfated polyanions. J. Virol. 63, 5489-5491.
25. NELSON, J.S., FEARON, K.L., NGUYEN, M.Q., McCURDY, S.N., FREDIANI, J.E., FOY, M.F., and HIRSCHBEIN, B.L. (1997). N3′ → P5′ oligodeoxyribonucleotide phosphoramidates: A new method of synthesis based on a phosphoramidite amine-exchange reaction. J. Org. Chem. 62, 7278-7287.
26. NORTON, J.C., PIATYSZEK, M.A., WRIGHT, W.E., SHAY, J.W., and COREY, D.R. (1996). Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14, 615-619.
27. OHNUMA, T., FENG, L.L., and HOLLAND, J.F. (1997). Inhibitory effects of telomeremimic phosphorothioate oligonucleotides on various human tumor cells in vitro. Anticancer Res. 17, 2455-2458.
28. PEYMANN, A., and UHLMANN, E. (1996). Minimally modified oligonucleotides-Combination of end capping and pyrimidine-protection. Biol. Chem. Hoppe-Seyler 377, 67-70.
29. PITTS, A.E., and COREY, D.R. (1998) Inhibition of human telomerase by 2′-O-methyl-RNA. Proc. Natl. Acad. Sci. USA 95, 11549-11554.
30. ROCKWELL, P., O'CONNOR, W.J., KING, K., GOLDSTEIN, N.I., ZHANG, L.M., and STEIN, C.A. (1997). Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 94, 6523-6528.
31. SARETZKI, G., SITTE, N., MERKEL, U., WURM, R.E., and VON ZGLINICKI, T. (1999). Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single-stranded DNA fragments. Oncogene 18, 5148-5158.
32. SHARMA, S., RAYMOND, E., SODA, H., SUN, D., HILSENBECK, S.G., SHARMA, A., IZBICKA, E., WINDLE, B., and VON HOFF, D.D. (1997). Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann. Oncol. 8, 1063-1074.
33. SHAY, J.W., and WRIGHT, W.E. (1996). Telomerase activity in human cancer. Curr. Opin. Oncol. 8, 66-71.
34. STEIN, C.A. (1996). Exploiting the potential of antisense: Beyond phosphorothioate oligonucleotides. Chem. Biol. 3, 319-323.
35. STEIN, C.A. (1997). Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 94, 6523-6528.
36. TARKANYI, I., HORVÁTH, A., SZATMARY, L, EIZERT, H., VAMOSI, G., DAMJANOVICH, S., SEGAL-BENDIRDJIAN, E., and ARADI, J. (2005). Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Lett. 579, 1411-1416.
37. VU, H., and HIRSCHBEIN, B.L. (1991). Internucleotide phosphite sulfurization with tetraethylthiuram disulfide. tetrahedron Lett. 32, 3005-3008.
38. WAN, M.S.K., FELL, P.L., and AKHTAR, S. (1998). Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev. 8, 309-317.
39. ZHANG, X., MAR, V., ZHOU, W., HARRINGTON, L., and ROBINSON, M.O. (1999). Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13, 2388-2399.